argenx SE (NASDAQ:ARGX) Shares Purchased by Tri Locum Partners LP

Tri Locum Partners LP grew its stake in shares of argenx SE (NASDAQ:ARGX) by 166.5% during the second quarter, Holdings Channel reports. The firm owned 74,558 shares of the company’s stock after purchasing an additional 46,577 shares during the period. argenx makes up approximately 8.1% of Tri Locum Partners LP’s investment portfolio, making the stock its 2nd largest position. Tri Locum Partners LP’s holdings in argenx were worth $32,063,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Profund Advisors LLC grew its position in shares of argenx by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 973 shares of the company’s stock valued at $418,000 after buying an additional 28 shares during the last quarter. Sei Investments Co. boosted its stake in argenx by 15.2% in the second quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock valued at $164,079,000 after acquiring an additional 50,477 shares in the last quarter. Simplify Asset Management Inc. purchased a new position in shares of argenx during the second quarter worth about $634,000. XTX Topco Ltd acquired a new stake in shares of argenx during the second quarter worth about $1,435,000. Finally, Wealth Alliance lifted its holdings in shares of argenx by 4.8% in the 2nd quarter. Wealth Alliance now owns 628 shares of the company’s stock valued at $270,000 after purchasing an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Bank of America restated a “buy” rating and set a $607.00 price target (up previously from $535.00) on shares of argenx in a research note on Monday, June 24th. Evercore ISI raised their target price on shares of argenx from $478.00 to $533.00 and gave the stock an “outperform” rating in a research report on Friday, July 12th. Piper Sandler upped their price target on shares of argenx from $522.00 to $535.00 and gave the company an “overweight” rating in a research report on Monday, June 24th. Robert W. Baird increased their price target on shares of argenx from $490.00 to $515.00 and gave the stock an “outperform” rating in a research note on Monday, July 29th. Finally, Wedbush lifted their price objective on shares of argenx from $519.00 to $560.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, argenx has an average rating of “Moderate Buy” and an average target price of $547.74.

argenx Price Performance

NASDAQ ARGX opened at $533.00 on Monday. The company has a market capitalization of $31.68 billion, a price-to-earnings ratio of -94.17 and a beta of 0.62. argenx SE has a 12 month low of $327.73 and a 12 month high of $554.74. The company’s fifty day moving average price is $512.59 and its two-hundred day moving average price is $433.06.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The firm had revenue of $489.43 million for the quarter, compared to analysts’ expectations of $436.66 million. During the same quarter in the prior year, the firm posted ($1.69) earnings per share. As a group, analysts anticipate that argenx SE will post -0.37 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.